Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00615563 |
The primary objective of this trial is to assess the presence of resistance to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective of this study is to examine clinicians? use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen. Ideally resistance testing will help clinicians identify active/sensitive ARVs needed to construct a rescue HAART regimen.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Behavioral: NO BI Drug administered |
Phase IV |
Study Type: | Observational |
Official Title: | Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study) |
Estimated Enrollment: | 260 |
Estimated Study Completion Date: | January 2008 |
Ages Eligible for Study: | 18 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Patients that meet the following inclusion criteria will be eligible for participation in this study:
Exclusion criteria
A patient with any of the following criteria will be excluded from participation in the study:
Study Chair: | Boehringer Ingelheim Study Coordinator | B.I. Pharmaceuticals,Inc./Ridgefield |
Study ID Numbers: | 1182.116 |
Study First Received: | January 31, 2008 |
Last Updated: | May 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00615563 |
Health Authority: | United States of America: Food and Drug Administration |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |